Biologica Technologies, a California-based innovator in biologic solutions, has successfully merged with Isto Biologics, a global leader in regenerative therapies. This merger integrates Advanced Biologics’ proprietary products into Isto’s esteemed Influx™ line of allografts. The collaboration leverages the expertise of both companies to accelerate patient healing. Advanced Biologics had a previous partnership with Isto, leading to the development of SPARC™, an innovative bone matrix. The integration enhances product offerings and fosters growth, promising improved patient outcomes. The combined team aims to provide top-notch products and support to surgeons in the field.
Advanced Biologics (known commercially as Biologica Technologies), a California-based company known for its innovative biologic solutions, announced today its successful merger with Isto Biologics, a global leader in regenerative and autologous therapies.
Biologica…tissue science evolved (PRNewsfoto/Biologica Technologies)
The merger will seamlessly integrate Advanced Biologics’ proprietary products into Isto’s esteemed and growing portfolio of allografts found within their Influx™ line.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We are thrilled for our entire Advanced Biologics/Biologica team to join forces with Isto Biologics, said Amit Govil, President of Advanced Biologics. “This merger brings together the clinical, commercial, and research-driven expertise of both companies and a shared commitment to help patients heal faster.”
Advanced Biologics has maintained a commercial partnership with Isto Biologics since 2020, catalyzed by the development of Isto’s Integrative Bone Matrix, SPARC™. SPARC is a novel inductive bone matrix that stemmed from Advanced Biologics’ proprietary tissue processing method used in their well-known allograft, OsseoGen®. SPARC is known for its increased levels of osteoinductive, chemotactic, angiogenic, and proliferative growth factors.
The integration of Advanced Biologics’ product commercialization initiatives into Isto’s growing allograft portfolio provides a unique opportunity to help patients heal faster and enable both customer bases to benefit from the broadened product set.
“Over the past four years, our collaboration with Advanced Biologics has been impressive,” said Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at Thompson Street Capital Partners (TSCP). “Investing in Advanced Biologics and embarking on this strategic combination amplifies both Isto’s and Advanced Biologics’ comprehensive biologics portfolios, paving a path forward for continued growth and patient healing.”
“With this merger, our combined team is now elevated with greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market,” said Don Brown, CEO of Isto Biologics.
Source: Biospace